Platelet activation may contribute to age-related cerebrovascular dysfunction by interacting with the endothelial cells that regulate the response to vasodilatory stimuli.This study evaluated the relationship between a platelet inhibitor, prostacyclin, and cerebrovascular reactivity (CVR) in healthy young (n = 35; 25 ± 4 years; 17 women, 18 men) and older (n = 12; 62 ± 2 years; 8 women, 4 men) adults, who were not daily aspirin users, before and after cyclooxygenase inhibition. Prostacyclin was determined by levels of 6-keto-prostaglandin F1α (6-keto PGF1α) in the blood. CVR was assessed by measuring the middle cerebral artery blood velocity response to hypercapnia using transcranial Doppler ultrasound before (CON) and 90 min after cyclooxygenase inhibition with indomethacin (INDO). In young adults, there were no associations between prostacyclin and middle cerebral artery CVR during CON (r = −0.14, P = 0.415) or INDO (r = 0.27, P = 0.118). In older adults, associations between prostacyclin and middle cerebral artery CVR during CON (r = 0.53, P = 0.075) or INDO (r = -0.45, P = 0.136) did not reach the threshold for significance. We also evaluated the relationship between prostacyclin and the change in CVR between conditions (ΔCVR). We found no association between ΔCVR and prostacyclin in young adults (r = 0.27, P = 0.110); however, in older adults, those with higher baseline prostacyclin levels demonstrated significantly greater ΔCVR (r = -0.74, P = 0.005). In conclusion, older adults with higher serum prostacyclin, a platelet inhibitor, may rely more on cyclooxygenase products for cerebrovascular reactivity to hypercapnia.
Platelet activation may contribute to age‐related cerebrovascular dysfunction by interacting with the endothelial cells that regulate the response to vasodilatory stimuli. The purpose of this study was to evaluate the relationship between a platelet inhibitor, prostacyclin, and cerebrovascular function in healthy young and older adults before and after cyclooxygenase inhibition. We hypothesized that higher levels of prostacyclin would be positively associated with cerebrovascular function. Healthy young (n=36; 25 ± 4 yrs; 19 women, 17 men) and older (n=12; 62 ± 2 yrs; 8 women, 4 men) adults who were not taking daily aspirin participated in the study. Prostacyclin was determined by levels of 6‐keto‐PGF1α in the blood. On a separate study visit, cerebrovascular function was assessed by cerebrovascular reactivity (CVR) to hypercapnia in the middle cerebral artery before (CON) and 90 minutes after cyclooxygenase inhibition with indomethacin (INDO) at 1.2 mg/kg. Participants were instrumented with a transcranial Doppler ultrasound which continuously recorded middle cerebral artery velocity, a nasal cannula to measure end‐tidal CO2, a finger blood pressure cuff to measure beat‐by‐beat blood pressure, and a mask with a one‐way valve to prevent rebreathing. CVR was calculated as the slope of the relationship between middle cerebral artery velocity and the change in end‐tidal CO2 during stepwise elevations in CO2. The associations between prostacyclin and CVR were analyzed using Pearson's Product‐Moment correlations. In young adults, there were no associations between prostacyclin and CVR during CON (r = 0.11, p = 0.54) or INDO (r = 0.15, p = 0.39). In older adults, there was a trend for an association between prostacyclin and CVR during CON (r = 0.52, p = 0.08), but no association during INDO (r = ‐0.41, p = 0.18). We also evaluated the relationship between prostacyclin and the change in CVR between conditions. We found no association in young adults (r = 0.15, p = 0.37); however, in older adults, those with higher baseline prostacyclin levels demonstrated a greater change in CVR (r = 0.69, p = 0.01). In conclusion, there was a trend for a positive association between platelet inhibition and cerebrovascular function in older adults. Furthermore, older adults may rely more on cyclooxygenase products to mediate CVR. Future studies could evaluate how platelet activation may contribute to age‐related changes in cerebrovascular function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.